Breaking News
February 25, 2018 - New staining method helps analyze 3D tissue samples using Nano-CT system
February 25, 2018 - Rare immune cell may prove to be potent weapon in fighting against cancer
February 25, 2018 - Connection between heart disease and cancer treatment
February 25, 2018 - Longer Endocrine Tx Better in Prostate Cancer
February 25, 2018 - Gene therapy restores normal blood glucose levels in mice with type 1 diabetes
February 25, 2018 - Desymmetrization paves way for new bioactive compounds
February 25, 2018 - Study finds underutilization of less expensive, post-acute care options for older adults
February 25, 2018 - UNIST researchers introduce new biosensing contact lens for diabetics
February 25, 2018 - Research consortium develops first 3D computer model of metabolic processes
February 25, 2018 - Adding hope to health messages may help promote preventative actions, researchers say
February 25, 2018 - Sudden Hearing Loss Recovery Hampered by Metabolic Syndrome
February 25, 2018 - First human trial of potentially game-changing diabetes treatment set to commence
February 25, 2018 - Child’s snacking patterns could be linked to genetics, study finds
February 25, 2018 - Patients with terminal cancer may be less competent to make big decisions
February 25, 2018 - Study highlights risks involved in short-term use of PICCs
February 25, 2018 - Study shows no increase in complications with ‘ad lib’ oral intake during labor
February 25, 2018 - Although Plaquenil (Hydroxychloroquine) Eases Rheumatoid Arthritis Pain it Won’t Help ‘Regular’ Arthritis
February 25, 2018 - Methotrexate May Help in Chronic Viral Arthritis
February 25, 2018 - Lack of guidance may delay a child’s first trip to the dentist
February 25, 2018 - Study shows cost-effectiveness of screening for fracture risk in older postmenopausal women
February 24, 2018 - Younger women with SCAD may benefit most from conservative treatment
February 24, 2018 - Blood Test for Concussion OK’d
February 24, 2018 - What are symptoms of an alcohol use disorder? – Rethinking Drinking
February 24, 2018 - Streamlined, cost-cutting post-treatment dental advice via iPad
February 24, 2018 - Researchers discover new regulator of the immune system
February 24, 2018 - Reducing red tape for traveling nurses
February 24, 2018 - Study supports benefits of meditation in control of attention and emotions
February 24, 2018 - Flu Vax Data ‘Only Tell Half the Story’
February 24, 2018 - Calculators – Rethinking Drinking – NIAAA
February 24, 2018 - From stem cells to a functional heart—the role of the Mesp1 gene
February 24, 2018 - Non-adherence to sleep apnea treatment linked to increased hospital readmissions
February 24, 2018 - Exercise-related posts influence health of social media pals
February 24, 2018 - Will Device Meetings in Europe Suffer Under New Ethics Rule?
February 24, 2018 - Nonstatin drug use increases by 124% in U.S., related expenditures triple
February 24, 2018 - Annual foot screening could help spot heart irregularities in people with diabetes
February 24, 2018 - Researchers developing rapid saliva test to detect Zika virus
February 24, 2018 - For Older Men, Even Light Exercise Helps
February 24, 2018 - Healthy Strategies to Beat Stress
February 24, 2018 - Cancer killing clue could lead to safer and more powerful immunotherapies
February 24, 2018 - Repeated sick days do not affect children’s learning ability, study shows
February 24, 2018 - New two-child policy in China could negatively affect women’s status and gender equality
February 24, 2018 - New research project to determine why mine dust-related lung diseases are on the rise
February 24, 2018 - A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology
February 24, 2018 - ClinicalTrials.gov: Child, Foster
February 24, 2018 - Study shows age doesn’t affect survival in patients with non-Hodgkin lymphoma after HCT
February 24, 2018 - Researchers explore how evolutionary processes guide pathways of cells
February 24, 2018 - Discovery may result in new medication to build stronger muscles in old age
February 24, 2018 - New study identifies possible target for treatment of dangerous allergic reactions
February 24, 2018 - Targeted vaccination can be successful in containing epidemic outbreaks
February 24, 2018 - Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
February 24, 2018 - ‘The Best Deals of Any Payer’: What We Heard This Week
February 24, 2018 - Blood and urine tests developed to indicate autism in children
February 24, 2018 - New low-cost microfluidic device brings single-cell technology to bedside
February 24, 2018 - Covestro and Pittsburgh Penguins announce multi-year unique partnership
February 24, 2018 - Children from low-income areas have poor outcomes after heart surgery, study finds
February 24, 2018 - Some genes can drive both metastasis and initial stages of tumor growth
February 24, 2018 - Visaris Americas announces installation of fully robotic Vision C digital X-ray suite at OGHS
February 24, 2018 - New discovery could accelerate clinical translation of stem cell-based therapies
February 24, 2018 - Respiratory disease patients with arthritis struggle to use complex inhalers
February 24, 2018 - FDA Alert: Labetalol Hydrochloride Injection by Hospira: Recall
February 24, 2018 - Flu, Tdap Vax Safe for Babies 6 Months Later
February 24, 2018 - Adults with autism show a diminished brain response to hearing their own name
February 24, 2018 - Study provides insight into neurobiology of dying
February 24, 2018 - Study finds tobacco smoke exposure among most adolescents in economically disadvantaged population
February 24, 2018 - U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections
February 24, 2018 - UCLA researchers use fluorescent colored proteins to trace origin of heart cells
February 24, 2018 - UC Riverside researchers discover way to halt cancer metastasis
February 24, 2018 - Home Routines Can Boost a Child’s Readiness for School
February 24, 2018 - FDA Investigating Misuse, Abuse of Gabapentinoids
February 24, 2018 - Scientists find key proteins control risk of osteoarthritis during aging
February 24, 2018 - Izon announce the launch of the qEV2 and qEV10 Exosome Isolation columns
February 24, 2018 - New CSIRO technology can create clean drinking water
February 24, 2018 - Treating sleep-disordered breathing may improve prognosis of heart failure patients
February 24, 2018 - More boys begin school a year late than girls, study finds
February 24, 2018 - Early life exposure to green space could have beneficial effects on cognitive function
February 24, 2018 - Joint Surgery: Aspirin Equals NOAC for Post-Acute VTE Prevention
February 23, 2018 - Scientists identify new marker of arthritis in mice
February 23, 2018 - Beetroot juice supplements may benefit patients with heart failure
February 23, 2018 - New study identifies novel molecular biomarkers of preeclampsia
February 23, 2018 - Researchers discover new link between gut bacteria and obesity
Researchers report technical advances in production of HIV vaccines

Researchers report technical advances in production of HIV vaccines

image_pdfDownload PDFimage_print

Research on HIV over the past decade has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very few candidate vaccines have been tested in clinical trials. One reason for this is the technical difficulty of manufacturing vaccines based on the envelope proteins of the virus, according to Phil Berman, who led development of a major component of the only vaccine to have shown any efficacy against HIV in a clinical trial.

Berman, the Baskin Professor of Biomolecular Engineering at UC Santa Cruz, has now developed new methods for the production of HIV vaccines. His approach solves major technical problems which have bedeviled the field. Berman described the new methods, and the candidate vaccines his lab has produced, in a talk at a conference on HIV vaccines held last week in Canada (“Emerging Technologies in Vaccine Discovery and Development,” a joint meeting with “Progress and Pathways Toward an Effective HIV Vaccine,” January 28 to February 1 in Banff, Alberta, part of the Keystone Symposia Global Health Series).

“Dozens of interesting vaccine candidates have been described, but most have not been tested in humans because it has not previously been possible to manufacture them affordably and in a timely fashion,” Berman said. “The technology we developed should break the logjam in HIV vaccine development, because it tremendously shortens the time, improves the yield, and lowers the cost.”

Berman’s lab was able to use robotics to shorten the time required to produce stable cell lines, needed to make the proteins for a vaccine, while at the same time greatly increasing how much of the protein the cell lines can produce. The improved yield makes it possible to reduce the size of the bioreactor needed to make vaccine for large clinical trials–from 200- to 10,000-liter vessels to 50- or 100-liter vessels–resulting in tremendous savings in the equipment required and cost of materials. In addition, Berman’s lab was able to create cell lines that make HIV envelope proteins with the right kind of carbohydrate components (called glycans) needed for an effective immune response.

“The carbohydrates attached to the protein are really important, something no one realized until recently,” Berman said. “The conventional way of making these envelope protein vaccines incorporated the wrong kind of carbohydrates. We now know that destroyed many of the important antigenic sites recognized by protective antibodies.”

Cell lines derived from Chinese hamster ovary (CHO) cells are the industry standard used to produce complex recombinant proteins for therapeutic use. These cells are also useful for the production of HIV vaccines. The gene for the desired protein is transferred into CHO cells in a process called transfection, and tens of thousands of transfected cells are screened to find the few rare cells that produce large amounts of the protein. The best cell lines are grown in large batches, in a process similar to yeast fermentation for making beer, and the proteins are then isolated and purified.

Berman’s lab developed a new robotic method to isolate high-producing cell lines making HIV envelope proteins. This shortened the time required to produce stable cell lines from 18 to 24 months to just 2 or 3 months, while increasing yields by a factor of 100 to 200. Those improvements are in comparison with Berman’s previous experience creating the AIDSVAX vaccine, first at Genentech and then at VaxGen.

AIDSVAX was one component of an experimental vaccine regimen used in a large-scale clinical trial known as RV144, which showed 31 percent efficacy in preventing new HIV infections. The RV144 results showed that protection was correlated with antibodies to a certain segment of an HIV envelope protein called gp120. Other research, however, revealed that many of the most potent antibodies (broadly neutralizing antibodies capable of neutralizing many different strains of HIV) actually recognize the carbohydrate components (glycans) attached to gp120.

“We realized that the original AIDSVAX vaccine had the completely wrong type of carbohydrate, and that we might improve the level of protection if we could find a way to make it with the proper type of carbohydrate,” Berman said.

So he and graduate student Gabriel Byrne set out to create a cell line that can produce the unusual glycans found on HIV envelope proteins rather than the complex glycans CHO cells normally produce. This was made possible by the powerful new gene editing technology known as CRISPR/Cas9. Berman’s lab used CRISPR to create a new cell line they called MGAT CHO, which produces proteins lacking complex glycans containing sialic acid and enriched for the simple “high mannose” type found on HIV envelope proteins. An unexpected benefit of this new cell line was that it enabled a simpler, less expensive process for recovering and purifying the proteins.

“People used to think carbohydrates are not immunogenic, but HIV turns everything on its head, and it turns out that the most important antibodies are directed to this unusual carbohydrate,” Berman said. “We can now make vaccines with it for the first time, and we’ve created an improved version of the vaccine used in the RV144 trial. Our hope is that it will bring the efficacy up from 31 percent to greater than 50 percent, the level likely required for product registration.”

Berman’s lab currently has two cell lines he said are ready to start producing vaccines on a large scale. He is now looking for partners and funding to bring them into clinical trials. One vaccine is an improved version of AIDSVAX that incorporates the right kind of glycans. The other is made from a strain of the virus called Clade C that is widespread in Southern Africa and India and accounts for the majority of new HIV infections worldwide.

Researchers have continued to use the AIDSVAX vaccine in clinical studies because it has been so hard to make new HIV vaccines, Berman said, noting that there have been 14 such studies since the RV144 results were released in 2009. “They’re still using that same old vaccine we made in the early 1990s. Although the stability and safety of the product is testament to the quality of the vaccine we made, new vaccines are required that take advantage of all that we have learned since that time,” he said. “It just emphasizes the need to find a more efficient way to make an HIV vaccine.”

In addition to Berman’s talk, several other members of his lab presented details of their methods and findings at the conference. Berman said they expect to publish their findings in several papers later this year. This research was funded by major grants from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Tagged with:

About author

Related Articles